Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 259.19M P/E - EPS this Y -85.40% Ern Qtrly Grth -
Income -106.79M Forward P/E -1.50 EPS next Y 1.20% 50D Avg Chg -12.00%
Sales 153.73M PEG 0.09 EPS past 5Y - 200D Avg Chg -28.00%
Dividend N/A Price/Book 1.39 EPS next 5Y -12.88% 52W High Chg -51.00%
Recommedations 1.80 Quick Ratio 4.39 Shares Outstanding 76.92M 52W Low Chg 5.00%
Insider Own 0.97% ROA -12.72% Shares Float 48.60M Beta 0.98
Inst Own 86.19% ROE -58.25% Shares Shorted/Prior 2.41M/2.41M Price 4.29
Gross Margin -17.36% Profit Margin -69.47% Avg. Volume 473,401 Target Price 12.89
Oper. Margin 37.95% Earnings Date May 13 Volume 258,401 Change -3.60%
About Sutro Biopharma, Inc.

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Sutro Biopharma, Inc. News
04/02/24 Sutro Biopharma, Inc. (NASDAQ:STRO) Analysts Just Cut Their EPS Forecasts Substantially
04/02/24 Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
03/26/24 Sutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances
03/25/24 Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates
03/25/24 Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
03/21/24 Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock Now
02/28/24 Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?
02/06/24 Sutro Biopharma to Participate in Upcoming Investor Conferences
01/04/24 Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC
12/18/23 Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Boosted 48% But Its Business Prospects Need A Lift Too
12/14/23 Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024
12/11/23 Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023
12/04/23 Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit
11/27/23 Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
11/21/23 Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer
11/13/23 Sutro Biopharma Inc (STRO) Reports Q3 2023 Financial Results and Business Updates
11/13/23 Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
11/13/23 Why Sutro Biopharma (STRO) Might Surprise This Earnings Season
11/04/23 Sutro Biopharma (NASDAQ:STRO) shareholders are up 11% this past week, but still in the red over the last three years
10/22/23 Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023
STRO Chatroom

User Image NotOfTheBody Posted - 4 hours ago

$STRO Stock closed on April 18th, 2023 at $4.51. One year later the stock is almost a buck lower and trading for under cash value. Now I know how McMurphy felt.

User Image TXcountry Posted - 5 hours ago

$STRO up up uh how is

User Image sudser71 Posted - 5 hours ago

$STRO I guess they shorted the fck out of er post financing.

User Image NotOfTheBody Posted - 6 hours ago

$STRO The stock is now on its way to closing down or staying flat (two days), 12 out of the last 13 trading days. Believe we're very close to the white flag up and waiving...lol.

User Image ViractaTrader77 Posted - 12 hours ago

$STRO Cantor Fitzgerald sees another strong year ahead for oncology M&A, with companies focused on antibody drug conjugates, radiopharmaceuticals and T-cell engagers expected to attract increased attention from major drugmakers looking to replenish pipelines. Impending patent cliffs will be a big motivator for deals. According to Cantor, around $182B in revenue is at risk over the next four years due to patent expirations, with oncology products accounting for 42% of that number. $VINC

User Image NotOfTheBody Posted - 1 day ago

$STRO The shorts, MM's along with the macro and geopolitical BS have scalped $2.19 (over 35%) off the intra-day high of $6.13 only 12-trading days ago on March 28th. Insane! Added more, this stock is beyond on sale. Bullish mid and long term. Would be bullish shorth term too if not for all this 10-year yield, macro and geopolitical noise that looks like it's unfortunately here to stay for a bit.

User Image ViractaTrader77 Posted - 1 day ago

ADC deals continues … it Merck acquires Abceutics Inc. for $208 million Caris Life Sciences partners with Merck KGaA, Darmstadt, Germany to discover and develop first-in-class ADCs. The deal is valued at $1.4B Kintara Therapeutics, Inc. NASDAQ: KTRA and TuHURA Biosciences, Inc. entered into a definitive agreement for an all-stock transaction: TORL BioTherapeutics, LLC raises an oversubscribed $158M Series B2 to advance its ADCs into the clinic: $VINC $STRO

User Image ViractaTrader77 Posted - 1 day ago

$STRO $VINC own both

User Image megamaven Posted - 1 day ago

$STRO offering at $5.18, current price entry seems positive.

User Image ViractaTrader77 Posted - 1 day ago

Sutro at Bat Folate Receptor Adc CO’s Immunogen acquired $10 billion Profound Bio acquired $1.8 billion Sutro Bio on sale at 1/6th market cap of Profound’s buyout with $6 in cash per share and deals with Ispen Pharma and Astellas!!! https://www.nature.com/articles/s41587-024-02168-5#:~:text=Pfizer's%20%2443%2Dbillion%20acquisition%20of,deal%20tally%2C%20according%20to%20BioCentury. $STRO $IBRX $IOVA $VKTX

User Image ViractaTrader77 Posted - 2 days ago

You do the math if a suitor bids $1.8 Billion for Sutro what’s the ROI??? https://twitter.com/BiotechTVHQ/status/1775900116924448891/mediaViewer?currentTweet=1775900116924448891&currentTweetUser=BiotechTVHQ $STRO $ELEV $PYXS $VINC

User Image ViractaTrader77 Posted - 2 days ago

No brainer acquisition for a big pharma for a billion dollars in equity for Sutro Biopharma. Nextgen $IMGN adc which was cornerstone of $ABBV deal- drug similar warhead. Tons of partnership money flowing in from Astellas and Ispen Pharma. Treasure trove of cash… this won’t last long….$STRO $GMAB just paid $1.8 billion for similar drug… easy 4x upside

User Image ViractaTrader77 Posted - 3 days ago

ADC Buying Spree… Sutro Biopharma up next? https://www.labiotech.eu/trends-news/antibody-drug-conjugates-investment-surge/ $STRO $CTMX $BOLT $XNCR

User Image TrustButVerifi Posted - 3 days ago

$STRO Screaming with the Highest Pitch BUY!!!

User Image ViractaTrader77 Posted - 4 days ago

Next up Sutro Biopharma https://www.biospace.com/article/genmab-leans-into-hot-adc-space-with-1-8b-profoundbio-acquisition-/ $STRO

User Image ViractaTrader77 Posted - 4 days ago

$IMGN $AMAM $VKTX $PYXS Trading beneath cash, tons of big pharma partnerships. 2 folate ADCs acquired in past 18 mos for $12 billion combined. Could be next major adc acquisition target. Do your homework on Sutro https://x.com/BiotechTVHQ/status/1775900116924448891

User Image FE123 Posted - 4 days ago

$STRO Why offering when they had 333 Million? Now over 400million in Cash. Guess more Funds wanted in?

User Image Trade_and_Profit Posted - 5 days ago

$STRO Looking into this stock what is a good entry price and is there any fear of further dilution

User Image ViractaTrader77 Posted - 5 days ago

$STRO

User Image Janes15 Posted - 5 days ago

$STRO Back to two bucks and back to the wood shed for STRO.

User Image TrustButVerifi Posted - 5 days ago

$STRO Another gift day, this is a SCREAMING BUY! 4/12/2024. $4.22

User Image RallyRaider Posted - 5 days ago

$STRO cant really find footing after biobucks deal

User Image TrustButVerifi Posted - 5 days ago

$STRO $VKTX Just for the Record VKTX is my #1 Holding Stro #2!

User Image SocioCobb Posted - 6 days ago

$STRO Right in the 50 sma 👀

User Image WLF2000 Posted - 6 days ago

$STRO glad to see some same folks from IMGN forum 🤭

User Image kubota2323 Posted - 6 days ago

$STRO

User Image TXcountry Posted - 6 days ago

$STRO to all the suckers that sold…

User Image TrustButVerifi Posted - 6 days ago

$STRO This thread is so dead and yet such a diamond for those who have discovered it! Congrats if you re here and long! we have 755 pair of eyes here, it will be 10 to 20 x as the stock price! 4/11/2024 !

User Image ViractaTrader77 Posted - 6 days ago

$STRO Worth $1.8 billion. $25 per share Same lead asset as Profound Bio and $6 cash per share Major buyout target

User Image ViractaTrader77 Posted - 6 days ago

Worth $10 a share right now! Price is a joke best kept ADC company diamond in the rough. Big Pharma just bought 2 direct folate receptor companies for $23 billion combined. I am sure they could fetch $2 billion right now considering they have enough cash to pay for their trials via an all stock deal. $STRO

Analyst Ratings
Piper Sandler Overweight Apr 3, 24
Oppenheimer Outperform Apr 3, 24
Truist Securities Buy Apr 3, 24
JMP Securities Market Outperform Apr 3, 24
Oppenheimer Outperform Mar 28, 24
Oppenheimer Outperform Mar 27, 24
Wedbush Outperform Mar 26, 24
JMP Securities Market Outperform Mar 26, 24
HC Wainwright & Co. Buy Mar 26, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
NEWELL WILLIAM J CEO CEO Mar 14 Buy 7.7508 10,000 77,508 116,525 03/15/22
Petree Daniel H Director Director Feb 08 Option 5.33 14,277 76,096 22,265 02/09/22